Lewy body pathology is more prevalent in older individuals with mitochondrial disease than controls by Erskine D et al.
Vol.:(0123456789) 
Acta Neuropathologica 
https://doi.org/10.1007/s00401-019-02105-w
CORRESPONDENCE
Lewy body pathology is more prevalent in older individuals 
with mitochondrial disease than controls
Daniel Erskine1,2  · Amy K. Reeve1,2 · Tuomo Polvikoski1,2 · Andrew M. Schaefer1,3 · Robert W. Taylor1,3 · 
Nichola Z. Lax1,2 · Omar El‑Agnaf4 · Johannes Attems2 · Gráinne S. Gorman1,2,3 · Doug M. Turnbull1,2,3 · Yi Shau Ng1,2,3
Received: 31 October 2019 / Revised: 22 November 2019 / Accepted: 22 November 2019 
© The Author(s) 2019
Mitochondrial diseases arise due to defects in mitochondrial 
DNA (mtDNA) or nuclear mitochondrial genes (nDNA), 
leading to impaired mitochondrial oxidative phospho-
rylation and dysfunction of organs with particularly high 
energy requirements. Primary mitochondrial diseases affect 
1 in 4300 individuals in the UK, making them amongst the 
most common heritable neurological conditions [2]. Mito-
chondrial dysfunction has also been linked to deposition of 
several sporadic age-associated pathologies, including neu-
rofibrillary tangles of hyperphosphorylated tau protein [3] 
and Lewy body (LB) pathology consisting of aggregated 
α-synuclein [4], pathological features of Alzheimer’s disease 
(AD) and Parkinson’s disease (PD)/dementia with Lewy 
bodies (DLB), respectively. Therefore, we sought to deter-
mine whether older individuals with mitochondrial diseases 
were at increased risk of developing age-associated neuro-
degenerative pathologies using post-mortem brain samples 
collected prospectively at Newcastle Brain Tissue Resource 
(NBTR).
We identified 17 cases with clinical and molecular con-
firmation of mitochondrial disease and sufficient tissue 
collected at NBTR between 2004 and 2019 (m.3243A>G 
N = 6; m.8344A>G N = 1; POLG N = 5; SDHA N = 1; 
RRM2B N = 1; multiple mtDNA deletions N = 2, single 
large-scale mtDNA deletion N = 1; Supplementary Table 1). 
Each case was stained with antibodies against hyperphos-
phorylated tau, amyloid-β and α-synuclein (Supplemen-
tary Data 1), and pathological stage was determined using 
international consensus guidelines [8]. We found that 5/17 
mitochondrial cases (29.4%) had LB pathology, whilst a 
case without LB had pathology consistent with progressive 
supranuclear palsy (PSP; case 7). In all cases, LB pathology 
was labelled by antibodies against fibrillar α-synuclein and 
α-synuclein phosphorylated at serine 129, as in idiopathic 
LB disease (Fig. 1). LB pathology occurred in 4/9 (44.4%) 
cases with nDNA mutations, whilst it was present only in 1 
case of mtDNA pathogenic variant (1/8; 12.5%). In contrast 
to LB pathology, amyloid-β and tau pathology were typical 
of the level observed in neurologically normal elderly brains 
and we found no evidence of age-associated pathologies such 
as TDP-43, age-related tau astrogliopathy and perivascular 
neuritic dystrophy (Supplementary Table 1). However, one 
case (case 11) had focal neocortical tau pathology, despite 
having no significant pathology in the entorhinal cortex or 
hippocampus (Supplementary Figure 1).
We compared the proportion of mitochondrial cases with 
LB pathology to that reported in all neurologically normal 
control cases aged over 50 collected at NBTR since 2010, 
the time at which all three pathologies were systematically 
evaluated using the aforementioned neuropathological 
guidelines in control cases (N = 82). LB pathology was less 
prevalent amongst control cases (9/82, 10.9%) than mito-
chondrial disease cases (5/17, 29.4%; χ2 = 3.94, p = 0.047), 
despite mitochondrial cases being significantly younger 
(63 ± 10 years) than controls (83 ± 12 years; p < 0.0001). The 
proportion of control cases with incidental LB pathology 
was similar to another report of LB prevalence in control 
cases over 60 years old [1].
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Despite the small size of this cohort, the present findings 
suggest LB pathology is more prevalent amongst older indi-
viduals with mitochondrial disease, particularly those with 
nDNA mutations, than in a comparable control population. 
Familial PD resulting from mitochondrial nDNA mutations 
does not always result in LB pathology, and the prevalence 
of LB pathology in Parkin cases is 33% based on reports 
from 18 cases, a comparable figure in a similarly sized 
cohort to our presently reported findings [6]. As mitochon-
drial dysfunction is associated with phenotypes of ageing 
[7], one could speculate that increased levels of LB pathol-
ogy in this population reflect an acceleration of ageing; 
however, as we did not find increased levels of other age-
associated pathologies, it seems unlikely that accelerated 
ageing alone could explain these findings. Nevertheless, it 
is difficult to make strong conclusions based on such a small 
Fig. 1  Lewy body pathology in mitochondrial disease cases. Repre-
sentative examples of LB pathology in the substantia nigra (a), amyg-
dala (b) and inferotemporal cortex (c) of case 2; LB pathology in 
the nucleus of Meynert of case 6 stained with KM51 (d), Syn-F2 (e) 
and pS129 (f); LB pathology in the amygdala of case 8 stained with 
KM51 (g), Syn-F2 (h) and pS129 (i); an LB in the substantia nigra 
of case 14 labelled with Syn-F2 (j), pS129 (k) and merged (l). Scale 
bars 100 µm (a–i), 5 µm (j–l)
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cohort, but we hope these findings will stimulate further 
study of LB pathology in this population.
The clinical significance of LB pathology in this popu-
lation is unclear as mitochondrial disease alone can cause 
significant neurodegeneration leading to parkinsonism and 
cognitive impairment [5] (Supplementary Data 2 and 3). We 
suggest the present findings highlight the need for further 
study of the prevalence of LB pathology in older mitochon-
drial disease patients. If confirmed in a larger cohort, the 
present findings suggest mitochondrial dysfunction and an 
elevated (though not absolute) risk of developing LB pathol-
ogy is a feature of both aged mitochondrial disease cases 
and some forms of familial PD characterised by mutations 
in mitochondrial proteins such as Parkin, raising questions 
about the distinction between these disorders. Further under-
standing of LB pathology in this population is important to 
understand its clinical relevance in the sub-set of mitochon-
drial diseases cases affected by it, and to determine the role 
of mitochondrial dysfunction in the genesis of LB pathology.
Acknowledgements This study was funded by the Wellcome Centre 
for Mitochondrial Research at Newcastle University (203105/Z/16/Z). 
D.E. is funded by an Alzheimer’s Research UK Fellowship (ARUK-
RF2018C-005). Y.S.N. holds a NIHR funded academic clinical lec-
tureship (CL-2016-01-003). Brain tissue was collected by Newcastle 
Brain Tissue Resource, which is funded in part by a Grant from the UK 
Medical Research Council (G0400074), by NIHR Newcastle Biomedi-
cal Research Centre awarded to the Newcastle upon Tyne NHS Founda-
tion Trust and Newcastle University, and by a Grant from the Alzhei-
mer’s Society and Alzheimer’s Research UK as part of the Brains for 
Dementia Research Project. The authors would like to thank Debbie 
Lett from Newcastle Brain Tissue Resource for her assistance with case 
identification, and Newcastle University Bioimaging Core Facility for 
assistance with confocal microscopy. The tissue for case 7 was pro-
vided with assistance from the Edinburgh Brain Bank and the authors 
would like to express their thanks to Professor Malcolm MacLeod and 
Professor Colin Smith. Molecular diagnoses were provided by the NHS 
“Rare Mitochondrial Disorders of Adults and Children Diagnostic 
Service” in Newcastle upon Tyne (https ://www.newca stle-mitoc hondr 
ia.com/), with funding from UK NHS Specialist Commissioners. The 
views expressed are those of the authors and not necessarily those of 
the NHS, the NIHR or the UK Department of Health.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. Frigerio R, Fujishiro H, Ahn TB, Josephs KA, Maraganore DM, 
DelleDonne A et al (2011) Incidental Lewy body disease: do some 
cases represent a preclinical stage of dementia with Lewy bodies? 
Neurobiol Aging 32:857–863. https ://doi.org/10.1016/j.neuro biola 
ging.2009.05.019
 2. Gorman GS, Schaefer AM, Ng Y, Gomez N, Blakely EL, Alston 
CL et al (2015) Prevalence of nuclear and mitochondrial DNA 
mutations related to adult mitochondrial disease. Ann Neurol 
77:753–759. https ://doi.org/10.1002/ana.24362 
 3. Melov S, Adlard PA, Morten K, Johnson F, Golden TR, Hinerfeld 
D et al (2007) Mitochondrial oxidative stress causes hyperphos-
phorylation of tau. PLoS ONE 2:e536. https ://doi.org/10.1371/
journ al.pone.00005 36
 4. Mullin S, Schapira A (2013) alpha-Synuclein and mitochondrial 
dysfunction in Parkinson’s disease. Mol Neurobiol 47:587–597. 
https ://doi.org/10.1007/s1203 5-013-8394-x
 5. Ng YS, Lax NZ, Bindoff LA, Turnbull DM (2019) Mitochon-
drial neurodegenerative disorders I: parkinsonism and cognitive 
deficits. Diagnosis and management of mitochondrial disorders. 
Springer, Cham, pp 223–239
 6. Schneider SA, Alcalay RN (2017) Neuropathology of genetic 
synucleinopathies with parkinsonism: review of the literature. 
Mov Disord 32:1504–1523. https ://doi.org/10.1002/mds.27193 
 7. Trifunovic A, Larsson NG (2008) Mitochondrial dysfunction as 
a cause of ageing. J Intern Med 263:167–178. https ://doi.org/10.
1111/j.1365-2796.2007.01905 .x
 8. Walker L, McAleese KE, Erskine D, Attems J (2019) Neurode-
generative diseases and ageing. Biochemistry and cell biology of 
ageing: part II clinical science. Springer, Singapore, pp 75–106
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
